Login / Signup

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment.

Shiyuan ZhouYingying ZhaiLingzhi YanXiaolan ShiJingjing ShangDe-Pei WuChengcheng FuSong Jin
Published in: Journal of clinical medicine (2023)
MM patients may also benefit from the dose-adjusted BU/CY regimen.
Keyphrases
  • end stage renal disease
  • high dose
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • low dose
  • cell therapy
  • peritoneal dialysis
  • prognostic factors
  • stem cells
  • acute lymphoblastic leukemia